Table 1.
Characteristics of patients surviving a minimum of 1, 3, 5, and 8 years from diagnosis.
| Died < 1 year from diagnosis (N = 156) | OS > 1 year from diagnosis (N = 2336) | OS > 3 years from diagnosis (N = 1573) | OS > 5 years from diagnosis (N = 977) | OS > 8 years from diagnosis (N = 429) | |
|---|---|---|---|---|---|
| a: Clinical and laboratory characteristics of patients surviving a minimum of 1, 3, 5, and 8 years from diagnosis. | |||||
| Age(years) Mean (SD) | 70.5 (11.3) | 63.2 (10.2) | 62.4 (10.1) | 61.5 (9.9) | 59.5 (9.9) |
| Age ≥ 65 years | 108 (69.2%) | 1105 (47.3%) | 687 (43.7%) | 398 (40.7%) | 139 (32.4%) |
| Sex (Male) | 90 (57.7%) | 1458 (62.4%) | 957 (60.8%) | 581 (59.5%) | 247 (57.6%) |
| ISS | |||||
| Missing (N) | 32 | 498 | 348 | 231 | 115 |
| ISS 1 | 11 (8.9%) | 483 (26.3%) | 347 (28.3%) | 228 (30.6%) | 106 (33.8%) |
| ISS 2 | 35 (28.2%) | 738 (40.2%) | 506 (41.3%) | 318 (42.6%) | 137 (43.6%) |
| ISS 3 | 78 (62.9%) | 617 (33.6%) | 372 (30.4%) | 200 (26.8%) | 71 (22.6%) |
| R-ISS | |||||
| Missing (N) | 46 | 686 | 480 | 306 | 144 |
| R-ISS 1 | 7 (6.4%) | 290 (17.6%) | 217 (19.9%) | 153 (22.8%) | 78 (27.4%) |
| R-ISS 2 | 57 (51.8%) | 1103 (66.8%) | 741 (67.8%) | 451 (67.2%) | 184 (64.6%) |
| R-ISS 3 | 46 (41.8%) | 257 (15.6%) | 135 (12.4%) | 67 (10.0%) | 23 (8.1%) |
| BMPC% Mean (SD) | 55.7 (30.2) | 50.0 (25.9) | 49.0 (25.6) | 47.1 (25.3) | 46.9 (25.7) |
| Missing (N) | 14 | 231 | 156 | 114 | 61 |
| Calcium ≥ 11 mg/dL | 23 (18.5%) | 187 (10.2%) | 98 (8.0%) | 48 (6.5%) | 15 (5.0%) |
| Missing (N) | 32 | 494 | 344 | 238 | 131 |
| Creatinine ≥ 2 mg/dL | 30 (24.4%) | 281 (15.0%) | 169 (13.3%) | 78 (10.2%) | 30 (9.8%) |
| Missing (N) | 33 | 465 | 299 | 209 | 124 |
| Albumin < 3.5 g/dL | 89 (70.1%) | 822 (46.3%) | 520 (44.7%) | 300 (42.9%) | 132 (43.4%) |
| Missing (N) | 29 | 561 | 409 | 277 | 125 |
| B2M > 5.5 mcg/mL | 77 (61.1%) | 609 (30.4%) | 371 (27.5%) | 199 (23.5%) | 71 (19.3%) |
| Missing (N) | 30 | 330 | 223 | 131 | 61 |
| Elevated LDH | 39 (36.4%) | 255 (15.5%) | 156 (14.2%) | 85 (12.5%) | 34 (11.1%) |
| Missing (N) | 49 | 688 | 476 | 297 | 124 |
| Platelets < 150/mcL | 42 (37.8%) | 215 (18.1%) | 136 (16.5%) | 82 (15.1%) | 29 (12.9%) |
| Missing (N) | 45 | 1146 | 750 | 435 | 204 |
| b: Cytogenetic characteristics and treatment regimens of patients surviving a minimum of 1, 3, 5 and 8 years from diagnosis. | |||||
| Normal FISH | 7 (4.5%) | 128 (5.5%) | 100 (6.4%) | 69 (7.1%) | 48 (11.2%) |
| HR IgH trans | 45 (29.0%) | 321 (14.0%) | 185 (12.0%) | 99 (10.3%) | 28 (6.6%) |
| Missing (N) | 1 | 42 | 29 | 15 | 2 |
| HR IgH trans/ 1q gain/ Ch17 Abn | 92 (75.4%) | 892 (49.0%) | 510 (44.1%) | 250 (38.2%) | 78 (29.7%) |
| Missing (N) | 34 | 514 | 417 | 323 | 166 |
| Double or Triple Hit | 31 (50.8%) | 174 (15.8%) | 84 (11.5%) | 33 (7.6%) | 9 (4.6%) |
| Missing (N) | 95 | 1232 | 843 | 540 | 235 |
| 1q gain | 58 (52.7%) | 514 (29.7%) | 276 (25.5%) | 109 (18.2%) | 33 (13.8%) |
| Missing (N) | 46 | 608 | 490 | 377 | 190 |
| Myc Abn | 14 (13.6%) | 145 (8.6%) | 83 (7.9%) | 45 (7.7%) | 11 (4.7%) |
| Missing (N) | 53 | 642 | 517 | 393 | 194 |
| 13q del | 16 (10.3%) | 233 (10.2%) | 137 (8.9%) | 88 (9.1%) | 30 (7.1%) |
| Missing (N) | 0 | 43 | 30 | 11 | 4 |
| Monosomy 13 | 75 (48.1%) | 830 (36.2%) | 539 (34.9%) | 316 (32.7%) | 124 (29.1%) |
| Missing (N) | 0 | 42 | 30 | 12 | 3 |
| Ch17 Abn | 36 (23.1%) | 288 (12.6%) | 158 (10.3%) | 86 (8.9%) | 31 (7.3%) |
| Missing (N) | 0 | 56 | 38 | 16 | 4 |
| 1st line Treatment | |||||
| Missing (N) | 29 | 140 | 70 | 43 | 20 |
| IMiD | 32 (25.2%) | 683 (31.1%) | 578 (38.5%) | 446 (47.8%) | 269 (65.8%) |
| PI | 51 (40.2%) | 667 (30.4%) | 474 (31.5%) | 275 (29.4%) | 63 (15.4%) |
| PI+IMiD | 25 (19.7%) | 758 (34.5%) | 388 (25.8%) | 167 (17.9%) | 51 (12.5%) |
| Other | 19 (15.0%) | 88 (4.0%) | 63 (4.2%) | 46 (4.9%) | 26 (6.4%) |
| SCT | 21 (13.5%) | 1376 (58.9%) | 1023 (65.0%) | 667 (68.3%) | 288 (67.1%) |
| Early SCT | 21 (13.5%) | 1161 (49.7%) | 834 (53.0%) | 530 (54.2%) | 209 (48.7%) |
B2M Beta2microglobulin, BMPCs Bone marrow plasma cells, ISS International staging system, LDH Lactate dehydrogenase, N number, OS Overall survival, R-ISS Revised international staging system, SD Standard deviation. Abn Abnormality, Ch17 Chromosome 17, Del Deletion, FISH Fluorescence In Situ Hybridization, HR High-risk, IMiD Immunomodulatory drug, N number, OS Overall survival, PI Proteasome inhibitor, SCT Stem cell transplant, trans translocation.